Almonertinib as First-line Treatment in Patients With EGFR+ Positive Pulmonary Adenosquamous Carcinoma or Combined Adenocarcinoma and Squamous Cell Carcinoma
Clinical trial NCT04354961 · UNKNOWN
Trial details
- NCT number
- NCT04354961
- Sponsor
- Fujian Cancer Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-05-07
- Primary completion
- 2023-12-31
- Enrollment
- 13
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.